Losartan Potassium Tablet, Film Coated
Product Images NDC 51655-418

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 51655-418). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 01)

Chemical structure of losartan potassium, illustrating the molecular arrangement of atoms including potassium ion (K+), chlorine, nitrogen rings, and hydroxy groups, consistent with the active ingredient in LOSARTAN POTASSIUM 50 mg tablets.*

FDA Label Image

Image002 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 02)

A line graph showing the percentage of patients with a primary endpoint over study months up to 66 months, comparing Losartan potassium (solid line) and Atenolol (dotted line). The graph indicates an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan potassium relative to Atenolol.*

FDA Label Image

Image003 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 03)

A line graph comparing the percentage of patients experiencing fatal or non-fatal stroke over study months for Atenolol (dotted line) and Losartan potassium (solid line). The graph shows a lower cumulative percentage for Losartan potassium with an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Image004 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 04)

A hazard ratio forest plot comparing event rates for Losartan Potassium and Atenolol across patient subgroups. The left panel shows primary composite event rates, and the right panel shows stroke (fatal/non-fatal) event rates. Data include age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD), with hazard ratios and confidence intervals displayed.*

FDA Label Image

Image005 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 05)

A line graph showing the percentage of patients with an event over 48 months comparing Losartan potassium and placebo groups. The vertical axis shows % patients with event up to 60%, and the horizontal axis represents time in months (0 to 48). The graph includes a note indicating a risk reduction of 16.1% with p=0.022.*

FDA Label Image

Label (51655 418 26 Master Bottle Label Approval Rev A 07 20)

Label for Losartan Potassium Tablets, USP 50 mg oral film-coated tablets by Northwind Health Company, LLC. The package contains 90 tablets and indicates prescription use only. Storage instructions specify 20°-25°C with excursions allowed between 15°-30°C, protected from light and out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.